Last reviewed · How we verify
NCT06281691
GreenBladder - Early Detection of Bladder Cancer in Residents in Greenland Using a Urinary Marker and a Mobile Cystoscopy Unit
trial testing Xpert® Bladder Cancer Detection Test in Urinary Bladder Neoplasms in 127 participants. Completed in 30 December 2025.
1 December 2025
Quick facts
| Lead sponsor | Jørgen Bjerggaard Jensen |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 127 |
| Start date | 28 December 2023 |
| Primary completion | 1 December 2025 |
| Estimated completion | 30 December 2025 |
| Sites | 2 locations across Denmark, Greenland |
Drugs / interventions tested
- Xpert® Bladder Cancer Detection Test
Conditions studied
- Urinary Bladder Neoplasms — all drugs for Urinary Bladder Neoplasms →
Sponsor
Jørgen Bjerggaard Jensen — full company profile →
Who can join
18 and older, any sex, with Urinary Bladder Neoplasms. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this observational study is to evaluate whether a urinary biomarker (Xpert® Bladder Cancer Detection Test) can be used as a selection tool to decide which patients that should undergo cystoscopy in haematuria work-up or in other indications where bladder tumor is suspected. Hereby, the investigators will investigate in which patients where cystoscopy can be omitted, particularly in areas with limited access to urological service. With these more selected investigations, patients with bladder tumors will potentially be selected to earlier diagnosis compared to the current non-selected investigations with the inherent logistic and economical challenges. With this strategy, the investigators aim at improving the current poor prognosis for bladder cancer patients in Greenland.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06281691
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Urinary Bladder Neoplasms
Currently open trials in the same condition.
- NCT07222488 — A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003) · Phase 1, PHASE2 · recruiting
- NCT06421142 — FAPI and FDG PET/MRI in Diagnosis and Therapy Prediction of Bladder Cancer · NA · active not recruiting
- NCT04369560 — Virtual Histology of the Bladder Wall for Bladder Cancer Staging · EARLY_PHASE1 · recruiting
- NCT06960577 — Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cance · Phase 3 · recruiting
- NCT06833073 — A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011) · Phase 2 · recruiting
Other Jørgen Bjerggaard Jensen trials
Trials by the same sponsor.
- NCT05337397 — Outpatient Laser Ablation of Recurrent Non-muscle Invasive Bladder Cancer · recruiting
- NCT05223491 — En Bloc Transurethral Resection of Non-muscle Invasive Bladder Cancer · NA · completed
- NCT04391790 — MOdified Urinary Conduit to Lower Strictures After radIcal Cystectomy · NA · unknown
- NCT04321707 — Complete Local Response to Neoadjuvant Chemotherapy in Patients With Muscle Invasive Bladder Cancer Evaluated by 15O-H2O · NA · completed
- NCT04138628 — Treatment Of Metastatic Bladder Cancer at the Time Of Biochemical reLApse Following Radical Cystectomy · Phase 2 · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06281691 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Jørgen Bjerggaard Jensen
- Last refreshed: 3 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06281691.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing